Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
May 18, 2006
By: Tim Wright
SFBC International, Inc. plans to cease all of its operations in Florida, including its Miami and Ft. Myers facilities. In addition, the company announced that the Miami-Dade County Unsafe Structures Board failed to issue an extension for reviewing the plans submitted by the company related to its planned structural improvements to the Miami facility. “SFBC International remains dedicated to providing the highest-quality, early and late phase clinical trial testing services to our clients,” said Jeffrey P. McMullen, president and chief executive officer of SFBC International. “The recent decision by the Unsafe Structures Board will further hinder our ability to restore profitability at our Miami operation, resulting in an acceleration of our review and decision to discontinue the operations of this part of the company. We will work closely with our clients to plan for an orderly completion of ongoing studies at these locations. Planned Phase I studies at Florida facilities will be directed where possible to our clinics in Quebec City, Montreal and in our new Toronto facility. When the various options were evaluated, it became evident that taking immediate, decisive action by shutting down our Florida operations would result in greater long-term value for our shareholders and clients. Removing the burden of the losses from the Florida operations as well as the previously estimated remediation costs for the facility in Miami, will enable us to dedicate our financial resources as well as our executive committee’s time to ensure the reputation and performance for the overall Company.” “We are withdrawing the guidance that we have provided for our 2006 financial results until we can provide updated guidance, including an estimate of the loss from discontinued operations,” stated David Natan, vice president and chief financial officer of SFBC International. “While the Florida operations were expected to account for approximately 10% of revenue in 2006, the losses from these operations were previously expected to impact our earnings from operations by approximately $7.5 million – $9.0 million in 2006.” The Miami-Dade County Unsafe Structures Board gave the company 60 days from May 17, 2006, to file for a permit to demolish the Miami facility. However, the company intends to appeal this ruling to the Florida courts and potentially file an injunction to stay these proceedings and to facilitate an orderly shut down of operations, as well as complete the transition of any studies to its Canadian facilities, where possible.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !